Floatz Rating
B60/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07595874CT.gov Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 | — | Recruiting | — | — | — |
NCT06575725CT.gov Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | — | Withdrawn | — | — | — |
NCT05627635CT.gov FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Botensilimab (this asset) | City of Hope Medical Center | P2 | B · 60 |
| Fluorouracilum | Merck Sharp & Dohme LLC | P3 | BBB |
| Irinotecan | Sun Yat-sen University | P3 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BBB |
| Cetuximab | Merck Sharp & Dohme LLC | P3 | BB |
| Nivolumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Floxuridine | City of Hope Medical Center | P2 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2/3 | BB |
+42 more in the Colon Adenocarcinoma cohort
Other indications for Botensilimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Adenocarcinoma | — | P2 | BB · 66 |
| Colorectal Cancer | — | P3 | B · 63 |
| Colorectal Carcinoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Botensilimab in Colon Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/botensilimab-colon-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →